Corcept Therapeutics Incorporated (CORT)

Currency in USD
63.62
-1.36(-2.09%)
Closed·
63.620.00(0.00%)
·
Advertisement
CORT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
62.8165.13
52 wk Range
28.66126.38
Key Statistics
Prev. Close
64.98
Open
64.07
Day's Range
62.81-65.13
52 wk Range
28.66-126.38
Volume
1.05M
Average Volume (3m)
1.25M
1-Year Change
-17.6866%
Book Value / Share
7.71
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CORT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
142.60
Upside
+124.14%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

4 Buy
0 Hold
1 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 142.60
(+124.14% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Piper Sandler
Buy173.00+171.93%165.00Maintain04/11/2026
Truist Securities
Buy164.00+157.78%-New Coverage18/08/2026
Piper Sandler
Buy165.00+159.35%88.00Maintain30/07/2026
H.C. Wainwright
Buy165.00+159.35%95.00Maintain30/07/2026
Canaccord
Buy150.00+135.77%135.00Maintain29/07/2026

Corcept Therapeutics Incorporated Earnings Call Summary for Q3/2026

  • Corcept Q3 revenue hit $340.5M, up 64% YoY, beating estimates; EPS of $1.01 topped forecast by 28%, but shares fell 2.4% after hours.
  • Lifyorli oncology drug generated $91.4M in second quarter on market, surging 92% sequentially; Korlym franchise contributed $249.1M.
  • Net income jumped to $126.8M from $43M in Q2; cash rose to $662M, supporting R&D and potential M&A amid strong operating leverage.
  • Management held 2026 revenue guidance at $1.1B-$1.2B unchanged despite beat, tempering investor enthusiasm and limiting stock gains.
  • FDA decision on relacorilant for Cushing's syndrome due Dec. 17; company advancing pipeline in oncology, MASH, and ALS indications.
Last Updated: 03/11/2026, 22:52
Read Full Transcript

Earnings

Latest Release
03/11/2026
EPS / Forecast
1.01 / 0.79
Revenue / Forecast
340.5M / 323.9M
EPS Revisions
Last 90 days

Compare CORT to Peers and Sector

Metrics to compare
CORT
Peers
Sector
Relationship
P/E Ratio
43.7x17.1x−0.2x
PEG Ratio
0.84−0.300.00
Price/Book
8.4x1.8x2.6x
Price / LTM Sales
7.2x2.0x2.6x
Upside (Analyst Target)
124.1%10.0%76.9%
Fair Value Upside
Unlock25.7%14.9%Unlock

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig’s disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Employees
730

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
31.75M29.01%2.15B
Other Institutional Investors
48.05M43.90%3.26B
Public Companies & Retail Investors
29.65M27.09%2.01B
Total
109.44M100.00%7.42B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.8.78%9,614,217651,748
Ingalls & Snyder, LLC7.25%7,934,507537,880

People Also Watch

163.81
RGEN
-3.81%
282.04
WCC
-8.18%
286.85
LGND
-0.03%
121.54
EWBC
-1.95%
55.12
ATRO
-5.50%

FAQ

What Is the Corcept (NASDAQ: CORT) Share Price Today?

The Corcept stock price today is 63.62 USD.

What Stock Exchange Does Corcept (CORT) Trade On?

Corcept is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Corcept?

The stock symbol (also called a 'ticker') for Corcept is "CORT."

What Is the Current Corcept Market Capitalisation?

As of today, Corcept (NASDAQ: CORT) market cap is 7.11B USD.

What Is Corcept's (CORT) Earnings Per Share (TTM)?

The Corcept EPS is currently 1.52 (Trailing Twelve Months).

When Is the Next Corcept Earnings Date?

Corcept's next earnings report will be released on 02/03/2027.

Is CORT a Buy or Sell From a Technical Analyst Perspective?

Based on today's Corcept moving averages and other technical indicators, the daily buy/sell signal for CORT stock is Strong Sell.

How Many Times Has Corcept Stock Split?

Corcept has split 0 times. (See the CORT stock split history page for full effective split date and price information.)

How Many Employees Does Corcept Have?

Corcept has 730 employees, based on their latest Companies House report.

What is the current trading status of Corcept (NASDAQ: CORT)?

As of 21/11/2026, Corcept (CORT) is trading at a share price of 63.62 USD, with a previous close of 64.98 USD. The stock has fluctuated within a day range of 62.81 USD to 65.13 USD, while its 52-week range spans from 28.66 USD to 126.38 USD.

What Is Corcept (CORT) Price Target According to Analysts?

The average 12-month price target for Corcept is 142.60 USD, with a high estimate of 173 USD and a low estimate of 50 USD. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +124.14% Upside potential.

What Is the CORT Premarket Price?

CORT's last pre-market stock price is 65.43 USD. The pre-market share volume is 850.00, and the stock has decreased by 0.45, or 0.69%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.